CANDI is a biocompatible succinyl‐cyclodextrin polymeric drug carrier with affinity for tumor‐associated macrophages.[38, 40] It contains small molecule drugs such as TLR7/8 agonist (R848), cIAP inhibitor (Lcl‐161), and a JAK1 inhibitor (ruxolitinib). The gene discussed is JAK1; the disease is neoplasm.